Sichuan Kelun Pharmaceutical Co., Ltd. is a China-based pharmaceutical manufacturer headquartered in Chengdu, Sichuan. The company develops, produces, and distributes sterile injectable medicines, with a core focus on large-volume parenteral (intravenous infusion) solutions and small‑molecule injectables. Its operations span multiple production sites in China and adhere to national and international GMP standards.
Kelun Pharmaceutical’s portfolio includes anti-infectives, oncology medicines, anesthesia and analgesia therapies, parenteral nutrition, and hospital-use fluids supplied to healthcare institutions in China and selected international markets. The company invests in R&D to advance injectable formulations and novel modalities; through affiliates such as Kelun‑Biotech it is active in biologics and antibody–drug conjugates, and collaborates with global pharmaceutical partners.
None yet. When a new project in the record names Kelun Pharmaceutical as owner, partner or investor, it shows here.
Merck receives $700M from Blackstone for sac-TMT development, retaining control over its progress and commercialization.
